中国寄生虫学与寄生虫病杂志 ›› 2011, Vol. 29 ›› Issue (2): 7-117-121.

• 论著 • 上一篇    下一篇

口服不同剂量三苯双脒对小鼠体内旋毛虫成囊期幼虫的作用

李润花1,高晋华1,王思飞2,裴彦江2,申金雁3,燕平梅1,殷国荣3 *   

  1. 1 太原师范学院生物系,太原 030031;2 山西医科大学七年制临床医学2007级,太原 030001;
    3 山西医科大学寄生虫学教研室,太原 030001
  • 出版日期:2011-04-30 发布日期:2012-09-27

Effect of Oral Administration of Tribendimidine at Different Dosages against Trichinella spiralis Encapsulated Larvae in Mice

 LI  Run-Hua-1, GAO  Jin-Hua-1, WANG  Si-Fei-2, PEI  Yan-Jiang-2, SHEN  Jin-Yan-3, YAN  Ping-Mei-1, YAN  Guo-Rong-3 *   

  1. 1 Department of Biology,Taiyuan Normal University,Taiyuan 030031,China;2 Department of Clinical Medicine,Shanxi Medical University,Taiyuan 030001,China;3 Department of Parasitology,Shanxi Medical University,Taiyuan 030001,China
  • Online:2011-04-30 Published:2012-09-27

摘要: 目的  观察口服不同剂量三苯双脒对小鼠横纹肌中旋毛虫成囊期幼虫的作用。 方法  8周龄BALB/c小鼠88只,随机均分为11组,每鼠口服感染旋毛虫成囊期幼虫50条。感染后第29天,分别口服三苯双脒50、100、150、200、250、300、350、400、450和500 mg/(kg·d),1次/d,连服6 d,同时设不服药对照组,治疗期间观察小鼠的不良反应。治疗结束后第7天,剖检各组小鼠,分别取膈肌、咬肌、胸肌和腓肠肌约0.1 g,压片法检查肌肉中的成囊期幼虫,观察其存活情况,并计数活虫数和死虫数,根据各组每克肌肉平均成囊期幼虫数评价疗效。 结果  三苯双脒50~300 mg/(kg·d)组小鼠未见不良反应;350和400 mg/(kg·d)组小鼠则有体毛蓬乱、消瘦和进食减少等现象,并有死亡,死亡率分别为25%和50%;而剂量450和500 mg/(kg·d)组小鼠在给药4 d和5 d后全部死亡。对照组小鼠膈肌中的成囊期幼虫总数最高,咬肌次之,胸肌和腓肠肌相近。感染小鼠用三苯双脒治疗时,50 mg/(kg·d)组无效,剂量为100 mg/(kg·d)或以上,随剂量增高,4个部位肌肉中的成囊期幼虫总数和活虫数均呈下降趋势。与对照组相比差别有统计学意义(P<0.05或P<0.01),其中300 mg/(kg·d)组小鼠膈肌、咬肌、胸肌和腓肠肌的活虫数分别为8.6±1.7、2.8±0.7、3.9±0.8和0,明显少于对照组的3 648.1±989.2、1 266.4±812.3、701.9±196.4和711.6±334.6(P<0.01),而350和400 mg/(kg·d)组4个部位肌肉中无活虫(P<0.01)。随三苯双脒剂量增高,4个部位肌肉中幼虫死亡率呈上升趋势,其中300 mg/(kg·d)组达98.6%~100%(P<0.01),350和400 mg/(kg·d)组则均为100%(P<0.01)。 结论  三苯双脒50 mg/(kg·d)对肌肉中旋毛虫成囊期幼虫虫荷无影响。300 mg/(kg·d)可有效杀死肌肉中的成囊期幼虫,为适宜剂量。而350 mg/(kg·d)或更高剂量对小鼠有不良反应或致死。

关键词: 三苯双脒, 旋毛形线虫, 成囊期幼虫, 疗效, 小鼠

Abstract: Objective   To observe the efficacy of oral administration of tribendimidine (TBD) at different dosages against Trichinella spirails encapsulated larvae in murine striated muscle.  Methods   A total of 88 BALB/c mice were divided equally into 11 groups. Each mouse was infected orally with 50 T.  spiralis encapsulated larvae. At day 29 after infection, TBD was each orally administered to mice of the 11 groups with doses of 0 (control group), 50, 100, 150, 200, 250, 300, 350, 400, 450, and 500 mg/(kg·d), respectively. All mice were administered once a day and lasted for 6 d, and untoward drug reactions for mice were observed. Mice were sacrificed at the 7th day after administration of TBD, the encapsulated larvae in diaphragmatic muscle, jugomaxillary muscle, pectoral muscle and gastrocnemius muscle were examined by pellet method, and the total, survival and dead worms were counted. The therapeutic effect was estimated on the basis of average quantity of encapsulated larvae per gram muscle.   Results   During the administration period, no untoward reaction were observed in mice of 50-300 mg/(kg·d) groups. Mice in 350 and 400 mg/(kg·d) groups showed body hair dishevelment, emaciation and food-intake decrease, death rates were 25% and 50%, respectively. All mice in 450 and 500 mg/(kg·d) groups died on day 4 and 5 after TBD administration, respectively. In control group, the highest total burden (per gram) was found in diaphragmatic muscle, followed by jugomaxillary muscle, gastrocnemius muscles and pectoral muscles. TBD at dose of 50 mg/(kg·d) was unable to kill encapsulated larvae. In the rest groups, with the increase of drug dose, the total worm burden and the number of survival worms showed a decreasing trend in four kinds of muscles, and were significantly lower than that of the control group (P<0.05 or P<0.01). In 300 mg/(kg·d) group the number of survival worms in diaphragmatic muscle, jugomaxillary muscle, pectoral muscle and gastrocnemius muscle [8.6±1.7, 2.8±0.7, 3.9±0.8, and 0, respectively] were significantly lower than that of the control group [3 648.1±989.2, 1 266.4±812.3, 701.9±196.4, and 711.6±334.6] (P<0.01). All encapsulated larvae in the four kinds of muscle died in 350 and 400 mg/(kg·d) groups. With the increase of TBD dosage, the mortality of encapsulated larvae increased in the muscles, reached up to 98.6%-100% in 300 mg/(kg·d) group (P<0.01), and 100% in 350 and 400 mg/(kg·d) groups (P<0.01).   Conclusion   Oral tribendimidine administered at 50 mg/(kg·d) to mice for 6 d is unable to reduce worm burden in muscle. Tribendimidine 300 mg/(kg·d) effectively kill encapsulated larvae and is a suitable dose against encapsulated larva stage. However, tribendimidine at doses of 350 mg/(kg·d) and above for 6 d is toxic to mice and even causing death.

Key words: Tribendimidine, Trichinella spiralis, Encapsulated larvae, Therapeutic Efficacy, Mouse